

Amendments to the Claims:

The following listing of claims will replace all prior versions of the claims in the application referenced above.

Listing of Claims:

Claims 1-15 (canceled)

Claim 16 (original): A hydrophilic matrix formulation suitable for once-a-day administration comprising:

- a) a valproate compound, and;
- b) said valproate compound in admixture with a sufficient quantity of a pharmaceutically acceptable polymer, so that said formulation exhibits the following in-vitro dissolution profile, when measured in a type 2 dissolution apparatus (paddle) at 100 rpm, at a temperature of $37 \pm 0.5^{\circ}\text{C}$, in 500ml of 0.1N HCl for 45 minutes, followed by 900ml of 0.05N phosphate buffer containing 75 mM sodium lauryl sulfate, pH5.5, for the remainder of the testing period:
 - i. no more than about 30% of total valproate is released after 3 hours of measurement in said apparatus;
 - ii. from about 40 to about 70% of total valproate is released after 9 hours of measurement in said apparatus;
 - iii. from about 55 to about 95% of total valproate is released after 12 hour of measurement in said apparatus, and;
 - iv. not less than 85% of total valproate is released after 18 hours of measurement in said apparatus.

Claims 17-18 (canceled)

Claim 19 (new): The formulation of claim 16 wherein the valproate compound is divalproex sodium.